What are the indications for Tremelimumab?

Tremelimumab is a CTLA-4 targeted immune checkpoint inhibitor whose main indication is the treatment of various solid tumors and advanced cancers. Its core mechanism is to block CTLA-4 signals, enable continuous activation of T cells, and improve the body's immune system's ability to recognize and eliminate tumor cells. Global clinical studies of this drug have shown that it has potential efficacy in a variety of cancers such as advanced hepatocellular carcinoma and non-small cell lung cancer (NSCLC), especially when combined with PD-1/PD-L1 inhibitors, the efficacy is more significant.

In regions such as the United States and Hong Kong, temsitumumab has been approved for immunotherapy in patients with advanced solid tumors. Its indications are mainly for patients who have failed chemotherapy or other standard treatments. The use strategies vary for different tumor types. For example, in advanced non-small cell lung cancer, it is often used in combination with Durvalumab; in advanced hepatocellular carcinoma, it can also be used in clinical trials of single agent or combination therapy. Its treatment principle emphasizes individualization and formulates treatment plans based on tumor type, gene expression and disease progression.

Tesetumumab has not yet been officially launched in mainland China, so there is no specific indication approval in China, but the clinical practice experience in Hong Kong and overseas provides a reference basis. Its indications are mainly concentrated in patients with feasible immunotherapy, tumor recurrence or refractory disease, which also reflects the precision and selectivity of modern immunotherapy. In the future, as more clinical trial results are released, its indications may be further expanded to cover more advanced or high-risk tumor types.

In short, the indications for temsitumumab are mainly advanced solid tumors, especially non-small cell lung cancer and hepatocellular carcinoma. Its use emphasizes the concept of precision immunotherapy, improving T cell activity by targeting CTLA-4, and providing new treatment options for patients with refractory tumors.

Reference: https://www.drugs.com/mtm/tremelimumab.html